Cargando…

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia

Detalles Bibliográficos
Autores principales:	Jensen, Christopher E., Montgomery, Nathan D., Galeotti, Jonathan, Foster, Matthew C., Zeidner, Joshua F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753433/ https://www.ncbi.nlm.nih.gov/pubmed/36444394 http://dx.doi.org/10.1111/jcmm.17608

Ejemplares similares

Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia
por: Deeb, Kristin K., et al.
Publicado: (2014)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor
por: Sandhöfer, Nadine, et al.
Publicado: (2016)

Myeloid sarcoma manifesting as generalized lymphadenopathy in a patient with myelofibrosis
por: Trennepohl, Christopher, et al.
Publicado: (2019)

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease
por: Johnson, Steven M., et al.
Publicado: (2023)

Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2019)

The synaptotagmin juxtamembrane domain is involved in neuroexocytosis
por: Caccin, Paola, et al.
Publicado: (2015)

Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia
por: Johnson, Steven M., et al.
Publicado: (2019)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia
por: Yang, Jingmei, et al.
Publicado: (2023)

Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence
por: He, Lijuan, et al.
Publicado: (2012)

Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
por: Wang, Xin, et al.
Publicado: (2014)

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
por: Hellesøy, Monica, et al.
Publicado: (2021)

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
por: de Aguirre, Itziar, et al.
Publicado: (2006)

Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations
por: Montgomery, Nathan D., et al.
Publicado: (2021)

Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia
por: Mahmood, Rafia, et al.
Publicado: (2019)

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
por: Murray, Heather C., et al.
Publicado: (2020)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog
por: Kato, Yuki, et al.
Publicado: (2015)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

Fusion with wild-type SNARE domains is controlled by juxtamembrane domains, transmembrane anchors, and Sec17
por: Orr, Amy, et al.
Publicado: (2022)

Computer simulations of the signalling network in FLT3 (+)-acute myeloid leukaemia – indications for an optimal dosage of inhibitors against FLT3 and CDK6
por: Buetti-Dinh, Antoine, et al.
Publicado: (2018)

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
por: Bitzer, Michael, et al.
Publicado: (2021)

Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center Experience
por: Borlenghi, Erika, et al.
Publicado: (2022)

Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia
por: Harrop, Sean, et al.
Publicado: (2023)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain
por: Estevam, Gabriella O., et al.
Publicado: (2023)

The juxtamembrane domain of the E-cadherin cytoplasmic tail contributes to its interaction with Myosin VI
por: Mangold, Sabine, et al.
Publicado: (2012)

The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain
por: Zornetta, Irene, et al.
Publicado: (2016)

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran
por: Parsa‐kondelaji, Mohammad, et al.
Publicado: (2022)

Exogenous hormone use, reproductive history and risk of adult myeloid leukaemia
por: Poynter, J N, et al.
Publicado: (2013)

Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits
por: Hilal, Talal
Publicado: (2020)

Novel Approaches to Target Mutant FLT3 Leukaemia
por: Müller, Jörg P., et al.
Publicado: (2020)

Hairy cell leukaemia with unusual BRAF mutations
por: Maitre, Elsa, et al.
Publicado: (2023)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features
por: Chauhan, Pradeep Singh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n38qsnjqm61bdtj23tvoao6fed